论文部分内容阅读
目的探讨曲美他嗪联合美托洛尔治疗冠状动脉粥样硬化性心脏病(CHD)伴心力衰竭患者的临床效果。方法选取2014年10月至2015年12月中国人民解放军第四六三医院收治的89例CHD伴心力衰竭患者作为研究对象,采用随机数字表法将其分为观察组(45例)与对照组(44例)。对照组患者给予常规对症治疗,观察组患者在对照组基础上采用曲美他嗪联合美托洛尔进行治疗,比较两组患者治疗前后心功能改善情况及临床疗效。结果治疗后,观察组患者的左心室收缩末期内径(LVESD)明显小于对照组,左心室射血分数(LVEF)明显高于对照组,心率(HR)明显低于对照组,差异均有统计学意义(均P<0.05);观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05)。结论对CHD伴心力衰竭患者在常规对症治疗基础上采用曲美他嗪联合美托洛尔进行治疗临床疗效明显,可有效改善其心功能。
Objective To investigate the clinical effect of trimetazidine and metoprolol in the treatment of patients with coronary heart disease (CHD) complicated with heart failure. Methods Eighty-nine CHD patients with heart failure admitted to the 463 Hospital of People’s Liberation Army from October 2014 to December 2015 were selected as study subjects, and were divided into observation group (45 cases) and control group by random number table method (44 cases). Patients in the control group were given conventional symptomatic treatment. Patients in the observation group were treated with trimetazidine combined with metoprolol on the basis of the control group. The improvement of cardiac function and clinical efficacy were compared between the two groups before and after treatment. Results After treatment, the left ventricular end systolic diameter (LVESD) in observation group was significantly lower than that in control group, the left ventricular ejection fraction (LVEF) was significantly higher than that in control group, and the heart rate (HR) was significantly lower than that in control group (P <0.05). The total effective rate of treatment in observation group was significantly higher than that in control group, the difference was statistically significant (P <0.05). Conclusion The clinical efficacy of trimetazidine combined with metoprolol in CHD patients with heart failure on the basis of conventional symptomatic treatment is obvious, which can effectively improve the cardiac function.